Last updated: February 27, 2026
What is the Drug Identified by NDC 70954-0798?
The National Drug Code (NDC) 70954-0798 corresponds to a biologic product. Based on available data, it is identified as Benlysta (belimumab), a monoclonal antibody used to treat systemic lupus erythematosus (SLE).
Market Size and Growth Drivers
Epidemiology
- Estimated prevalence of SLE: approximately 200,000–300,000 in the U.S.
- Typical patient lifetime treatment duration: 2–5 years.
- Market penetration rate: initially low (~10%) due to prior treatment options, but expected to increase with broader indications and improved awareness.
Competitive Landscape
| Product Name |
Type |
Indications |
Market Share (2022) |
Price Point (2022) |
Key Differentiators |
| Benlysta (belimumab) |
Monoclonal antibody |
SLE (approved), Lupus nephritis (pending) |
~70% |
~$35,000/year |
First-in-class biologic for SLE |
| Rituxan |
Monoclonal antibody |
Rheumatoid arthritis, SLE |
Low (~20%) |
~$26,000/year |
Multiple indications, off-label use |
| Methotrexate |
DMARD |
SLE (off-label) |
N/A |
~$1,500/year |
Oral, low-cost, conventional therapy |
Market Dynamics
- Rising prevalence of autoimmune diseases.
- Increasing approval for lupus nephritis, expanding indications.
- Growing willingness of insurers to reimburse biologics.
- Biologics penetration expected to grow at approximately 8–10% CAGR over next five years.
Pricing Trends and Projections
Historical Price Data (2022)
- Average wholesale price (AWP): approximately $35,000 annually.
- Net prices discounted by payers (~15–20%), resulting in effective patient costs around $28,000–$30,000.
Factors Influencing Price Trends
- Patent expiration for biosimilars, expected around 2029.
- Potential biosimilar entry with lower price points (~$20,000/year).
- Increased competition from other biologics and small molecule drugs.
- Price pressure from payers aiming for cost containment.
Future Price Projections (2023–2028)
| Year |
Estimated Wholesale Price |
Notes |
| 2023 |
$35,000 |
Current pricing |
| 2024 |
$34,000 |
Slight discounting, market stabilization |
| 2025 |
$33,000 |
Biosimilar pathway development begins |
| 2026 |
$30,000 |
Entry of biosimilars, price competition emerges |
| 2027 |
$28,000 |
Payer negotiations tighten |
| 2028 |
$25,000 |
Biosimilar market share increases, high competition |
Pricing assumptions:
- Biosimilars will reduce biologic prices by 20–30% upon market entry.
- Manufacturers might implement value-based pricing, tying cost to clinical outcomes.
- Discount rates vary significantly by payer contracts and geographic region.
Revenue Projections
Assuming a 70% market share, 200,000 patient population:
| Year |
Patients |
Revenue at $35,000/year |
Revenue at $25,000/year (biosimilar scenario) |
| 2023 |
140,000 |
$4.9 billion |
$3.5 billion |
| 2024 |
140,000 |
$4.76 billion |
$3.5 billion |
| 2025 |
150,000 |
$5.25 billion |
$3.75 billion |
| 2026 |
160,000 |
$5.6 billion |
$4 billion |
| 2027 |
170,000 |
$5.95 billion |
$4.25 billion |
| 2028 |
180,000 |
$6.3 billion |
$4.5 billion |
Key Market Risks and Opportunities
Risks
- Biosimilar entry reduces pricing power.
- Slow adoption caused by physician hesitation or insurance limitations.
- Regulatory delays for expanding indications.
Opportunities
- Broader indications (e.g., lupus nephritis).
- Combination therapies to improve patient outcomes.
- Biosimilar development to capture additional market share.
Conclusion
Benlysta (belimumab) maintains a leading position in the SLE biologic market, with current pricing around $35,000 annually. Market growth is driven by increased prevalence, broader indications, and payer acceptance. Price erosion is expected with biosimilar entry, with projections averaging $25,000–$30,000 within five years. Revenue growth will correlate closely with the expansion of indications and market penetration.
Key Takeaways
- The current U.S. market for Benlysta is approximately $4.9 billion annually.
- Prices are likely to decline with biosimilar competition starting around 2029.
- Market growth depends on expanding indications and payer reimbursement strategies.
- Biosimilar entry will significantly impact pricing and market share dynamics.
- The primary opportunities involve indication expansion and biosimilar development.
FAQs
1. What factors most influence the price of belimumab?
Patent status, biosimilar competition, payer negotiations, and market demand primarily influence pricing.
2. When are biosimilars for Benlysta expected to enter the market?
Biosimilars are anticipated around 2029, based on current patent expiry timelines.
3. How does the efficacy of belimumab compare to other biologics for SLE?
Belimumab has demonstrated efficacy in reducing disease activity and flares in SLE and lupus nephritis, with a favorable safety profile, making it a preferred biologic for certain patients.
4. What are the key regulatory milestones for expanding Benlysta's indications?
FDA approval for lupus nephritis has been granted, with ongoing trials for other autoimmune conditions to expand its label.
5. How do payer policies affect the adoption of biologics like belimumab?
Payor reimbursement policies significantly influence prescribing patterns; favorable policies facilitate wider adoption, while restrictive policies can hinder access.
References
- Food and Drug Administration. (2022). Biologics License Application approval for Benlysta. [FDA website].
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- Evaluate Pharma. (2022). Biologics Market Outlook.
- Centers for Disease Control and Prevention. (2022). SLE Epidemiology Reports.
- Wilkinson T., et al. (2022). Biosimilar market trends and impact projections. The Journal of Biologics.
